摘要:在所有乳腺癌分子亚型中,人表皮生长因子受体(Her-2)表达阴性的约占85%,数量庞大,由于靶向治疗效果欠佳,因此手术,化疗和放疗成为Her-2阴性乳腺癌重要治疗手段,其中,在手术之前进行新辅助化疗拥有有效地降低临床分期,提高肿瘤切除率,降期保乳保腋窝,提供体内药敏信息等众多优势在Her-2阴性乳腺癌的治疗中发挥着至...
in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort[J].Lancet, 2010, 375(9712):377-384.
徐建明教授表示,在局部进展期 HER-2 阳性晚期胃癌的围手术期治疗上,抗 HER-2 联合免疫治疗未来或将大有可为,相信国内外应该很快会开展这方面的研究,期待该领域能够取得更多突破,最终让患者获得更长、更好生存。 专家简介 沈琳 教授 北京大学肿瘤医院 消化肿瘤内科主任、I 期临床试验病房主任 历任北京大学肿瘤医院副...
徐建明教授表示,在局部进展期 HER-2 阳性晚期胃癌的围手术期治疗上,抗 HER-2 联合免疫治疗未来或将大有可为,相信国内外应该很快会开展这方面的研究,期待该领域能够取得更多突破,最终让患者获得更长、更好生存。 专家简介 沈琳 教授 北京大学肿瘤医院 消化肿瘤内科主任、I 期临床试验病房主任 历任北京大学肿瘤医院副...
6. Chemotherapy regimens should not be tailored to different breast cancer subtypes (such as triple-negative or lobular disease) because there is currently no evidence of differential efficacies. In addition, in vitro chemoresistance assays should not be used to select treatment. ...
RESULTS: One hundred eighty-two enrolled patients received ≥1 dose of HER3-DXd. Patients had a median of five previous therapies for advanced disease. Efficacy results are reported across clinical subtypes: hormone receptor-positive (HR+)/human epidermal grow...
Sivarajan L,Sivarajan K M,Natarelli J,et al.Change in HER-2/neu status from negative to positive following treatment in breast cancer:A case report[J].Case Rep Oncol,2011,4(1):19-24.Sivarajan L, Sivarajan KM, Natarelli J, et al. Change in HER-2/neu status from negative to ...
01-关于her-2阴性胃癌治疗 根据现行国际各大指南标准[5]，铂类联合氟尿嘧啶类药物为基础的全身化疗是晚期 HER-2 阴性胃癌的一线标准治疗，且化疗通常持续至直至疾病进展。然而铂类药物的累积毒性通常会使患者的身体状态进一步恶化。临床中，患者持续化疗至出现无法耐受的毒性后，通常使用氟尿嘧啶类药物单药治疗。此外，...
For the larger hormone-receptor positive and Her-2 negative subgroup, which concerns 75% of the patients, endocrine therapy and chemotherapy may be considered. Looking toward new-targeted therapies, this paper reviews the current use of these two treatment modalities in adjuvant, neoadjuvant and ...
Background: The everolimus–exemestane pair was approved by the US Food and Drug Administration (FDA) in 2012 to treat women with hormone receptor-positive (ER+), HER2-negative metastatic breast cancer (MBC) that got worse after treatment with aromatase inhibitor alone. The main benefit of this...